Skip to main content
SpringerLink
Log in

A Systematic Scoping Review of the State of Pharmacovigilance and Governance in the MENA Region: Challenges and Opportunities

  • Systematic Review
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

Introduction

Pharmacovigilance (PV) systems around the world vary in capacity and maturity. Many factors can influence PV.

Objectives

This systematic scoping review aims to explore the opportunities for effective PV in the Middle East and North Africa (MENA) region by (1) using the pharmacogovernance (PG) framework to evaluate the PV systems and (2) determining the factors influencing PV, including regulatory governance, PG, and international actors influence.

Methods

In accordance with Cochrane Collaboration guidelines, the STARLITE criteria were used to guide the systematic literature search and review process. The search included English and Arabic language databases, search engines, and grey literature and a supplementary search of the reference lists of included articles. Inclusion criteria were pertinent to the influence of PV, governance and health, PG framework domains, international actors, and MENA countries. Data synthesis followed the meta-aggregation process.

Results

From the 32 included records, the majority of PV-enhanced actions were from Saudi Arabia, Iran, and Morocco. The ‘policy, law, and regulations’ domain was the strongest in the MENA, whereas public ‘participation and representation’ was lacking. Further, the PG framework allowed the identification of shortcomings, including a lack of public inclusiveness and participation, resource scarcity, misalignment of resource allocation, issues with existing regulations, and deficiencies in ‘accountability and transparency’.

Conclusion

Most of the existing systems are still in their infancy, and disparities exist at national and regional levels. The operationalization of effective PV systems requires actions that assure (1) the development and enforcement of comprehensive regulations, (2) adequate and equitable aid for core PV processes, and (3) accountability and participation from all stakeholders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization. The importance of pharmacovigilance-safety monitoring of medicinal products. Geneva: WHO; 2002.

    Google Scholar 

  2. Pharmacovigilance WH. Ensuring the safe use of medicines, WHO policy perspective of medicine. Geneva: WHO; 2004. p. 1222–39.

    Google Scholar 

  3. Supporting pharmacovigilance in developing Countries: the systems perspective. 1st ed. Arlington: Management Sciences for Health; 2009 [cited 8 Mar 2017]. http://apps.who.int/medicinedocs/documents/s18813en/s18813en.pdf.

  4. Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low-and-middle-income countries. Drug Saf. 2010;33(8):689–703.

    Article  PubMed  Google Scholar 

  5. Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449–60.

    Article  CAS  PubMed  Google Scholar 

  6. The Middle East and North Africa. Worldbank.org. 2017 [cited 25 Mar 2017]. http://www.worldbank.org/en/region/mena.

  7. Ahmad SR. Pharmacovigilance bolstered in the Arab world. Lancet. 2014;384(9960):e63.

    Article  PubMed  Google Scholar 

  8. Bham B. The first Eastern Mediterranean region/Arab countries meeting of pharmacovigilance. Drugs Real World Outcomes. 2015;2(1):111–5.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Moscou K, Kohler JC, MaGahan A. Governance and pharmacovigilance in Brazil: a scoping review. J Pharm Policy Pract. 2016;9(1):3.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Mackey TK, Liang BA. Combating healthcare corruption and fraud with improved global health governance. BMC Int Health Hum Rights. 2012;12(1):23.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Baghdadi‐Sabeti G, Cohen-Kohler J, Wondemagegnehu E. Measuring transparency in the public pharmaceutical sector-Assessment instrument. Geneva: World Health Organization, Departments of Essential Medicines and Pharmaceutical Policies and Ethics, Equity, Trade and Human Rights; 2009.

  12. Moscou K, Kohler JC. Matching safety to access: global actors and pharmacogovernance in Kenya—a case study. Global Health. 2017;13(1):20.

    Article  PubMed  PubMed Central  Google Scholar 

  13. United Nations Development Programme. Governance for sustainable human development: a UNDP policy document. New York: United Nations Development Programme; 1997.

    Google Scholar 

  14. Annan KA. Partnerships for global community: annual report on the work of the organization, 1998. United Nations, Department of Public Information; 1998.

  15. Siddiqi S, Masud TI, Nishtar S, Peters DH, Sabri B, Bile KM, Jama MA. Framework for assessing governance of the health system in developing countries: gateway to good governance. Health Policy. 2009;90(1):13–25.

    Article  PubMed  Google Scholar 

  16. Anello E. A framework for good governance in the public pharmaceutical sector. Geneva: World Health Organization, Department of Essential Medicines and Pharmaceutical policies; 2008.

    Google Scholar 

  17. Ratanawijitrasin S, Wondemagegnehu E. Effective drug regulation. A multicountry study. Geneva: World Health Organization; 2002.

    Google Scholar 

  18. Moscou K, Kohler JC, Lexchin J. Drug safety and corporate governance. Glob Health Gov. 2013;7(1):68–9.

  19. Rentz ED, Lewis L, Mujica OJ, Barr DB, Schier JG, Weerasekera G, Kuklenyik P, McGeehin M, Osterloh J, Wamsley J, Lum W. Outbreak of acute renal failure in Panama in 2006: a case–control study. Bull World Health Organ. 2008;86(10):749–56.

    Article  PubMed  PubMed Central  Google Scholar 

  20. WHO Uppsala Monitoring Centre (UMC). The WHO Programme. [cited 15 Mar 2017]. http://www.who-umc.org.

  21. Tsintis P, La Mache E. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications. Drug Saf. 2004;27(8):509–17.

    Article  PubMed  Google Scholar 

  22. Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19(1):1.

    Article  CAS  PubMed  Google Scholar 

  23. Nwokike J. Technical assistance for the establishment of a pharmacovigilance and medicine safety system in Rwanda. Submitted to the US Agency for International Development by the Strengthening Pharmaceutical Systems (SPS) Program. Arlington: Management Sciences for Health; 2009.

  24. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. New York: Wiley; 2011.

    Google Scholar 

  25. Supplemental Handbook Guidance | Cochrane Qualitative and Implementation. Methods.cochrane.org. 2017 [cited 15 May 2017]. http://methods.cochrane.org/qi/supplemental-handbook-guidance.

  26. Armstrong R, Hall BJ, Doyle J, Waters E. ‘Scoping the scope’of a Cochrane review. J Public Health (Oxf). 2011;33(1):147–50.

    Article  Google Scholar 

  27. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Schöpfel J, Farace DJ. Grey literature. Encyclopedia of library and information sciences. 3rd ed. Boca Raton, FL: CRC Press; 2009. p. 2029–39.

  29. Munro S, Lewin S, Smith H, Engel M, Fretheim A, Volmink J. Adherence to tuberculosis treatment: a qualitative systematic review of stakeholder perceptions. PLOS Medicine. 2007;4(7):e238.

  30. Noyes J, Lewin S. Chapter 5: extracting qualitative evidence. Supplementary guidance for inclusion of qualitative research in Cochrane systematic reviews of interventions. Version. 2011;1:1–24.

  31. Wilbur K. Pharmacovigilance in Qatar: a survey of pharmacists/Pharmacovigilance au Qatar: enquete aupres des pharmaciens. East Mediterr Health J. 2013;19(11):930.

    CAS  PubMed  Google Scholar 

  32. Wilbur K. Pharmacovigilance in the Middle East. Drug Saf. 2013;36(1):25–30.

    Article  PubMed  Google Scholar 

  33. Shalviri G, Mohammad K, Majdzadeh R, Gholami K. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. Pharmacoepidemiol Drug Saf. 2007;16(10):1136–40.

    Article  PubMed  Google Scholar 

  34. Bencheikh RS, Benabdallah G. Medication errors: pharmacovigilance centres in detection and prevention. Br J Clin Pharmacol. 2009;67(6):687–90.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Baniasadi S, Habibi M, Haghgoo R, Gamishan MK, Dabaghzadeh F, Farasatinasab M, Farsaei S, Gharekhani A, Kafi H, Karimzadeh I, Kharazmkia A. Increasing the number of adverse drug reactions reporting: the role of clinical pharmacy residents. Iran J Pharm Res. 2014;13(1):291.

    PubMed  PubMed Central  Google Scholar 

  36. Baniasadi S, Fahimi F, Shalviri G. Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol. 2008;102(4):408–11.

    Article  CAS  PubMed  Google Scholar 

  37. Al-Worafi YM. Comment on: “Pharmacovigilance in the Middle East”. Drug Saf. 2014;37(8):651.

    Article  PubMed  Google Scholar 

  38. Alshammari TM, Wa’ad H, Le Louet H, Aljadhey HS. Completeness of adverse drug reactions reports of the Saudi adverse event reporting system. Saudi Med J. 2015;36(7):821–8.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wilbur K. How to improve suspected ADR reporting among pharmacists in the GCC? Saudi Pharm J. 2016;24(6):718.

    Article  PubMed  Google Scholar 

  40. Khan LM, Al-Harthi SE, Alkreathy HM, Osman AM, Ali AS. Detection of adverse drug reactions by medication antidote signals and comparison of their sensitivity with common methods of ADR detection. Saudi Pharm J. 2015;23(5):515–22.

    Article  PubMed  Google Scholar 

  41. Alshammari T, Alshakka M, Aljadhey H. Pharmacovigilance system in Saudi Arabia. Saudi Pharm J. 2017;25(3):299–305.

    Article  PubMed  Google Scholar 

  42. Aljadhey H, Mahmoud MA, Alshammari TM, Al-Dhaeefi M, Le Louet H, Perez-Gutthann S, Pitts PJ. A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia. Saudi Med J. 2015;36(9):1097–102.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Swamy S, Mourya M, Kadhe G, Mane A, Sawant S. Safety reporting through a comprehensive and pragmatic pharmacovigilance process for India and emerging markets: an industry perspective. Expert Opin Drug Saf. 2015;14(9):1409–20.

    Article  PubMed  Google Scholar 

  44. Cheaib N. Pharmacovigilance in clinical trials: current practice and challenges. Account Res. 2016;23(1):23–30.

    Article  CAS  PubMed  Google Scholar 

  45. Batniji R, Khatib L, Cammett M, Sweet J, Basu S, Jamal A, Wise P, Giacaman R. Governance and health in the Arab world. Lancet. 2014;383(9914):343–55.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Baniasadi S, Fahimi F, Namdar R. Development of an adverse drug reaction bulletin in a teaching hospital. Formulary. 2009;44:333–5.

    Google Scholar 

  47. Yadav S. Status of adverse drug reaction monitoring and pharmacovigilance in selected countries. Indian J Pharmacol. 2008;40(Suppl 1):S4–9.

    PubMed  PubMed Central  Google Scholar 

  48. Peiravian F. Parallel import: is it worth? Iran J Pharm Res. 2014;13(4):1111.

    PubMed  PubMed Central  Google Scholar 

  49. Shalviri G, Valadkhani M, Dinarvand R. Ten years pharmacovigilance activities in Iran. Iran J Public Health. 2009;38(Suppl 1):162–5.

    Google Scholar 

  50. Shankar P, Jha N, Aljadhey H, Pitts P. A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia. Saudi Med J. 2015;36(11):1369–70.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Wilby KJ, Hazi HM, Ashour MA. Development, implementation and evaluation of a medication safety programme for schoolchildren in Qatar/Developpement, mise en oeuvre et evaluation d’un programme de surete des medicaments pour les ecoliers au Qatar. East Mediterr Health J. 2015;21(1):62.

    Article  CAS  PubMed  Google Scholar 

  52. Gholami K, Shalviri G, Zarbakhsh A, Daryabari N, Yousefian S. New guideline for tramadol usage following adverse drug reactions reported to the Iranian Pharmacovigilance Center. Pharmacoepidemiol Drug Saf. 2007;16(2):229–37.

    Article  CAS  PubMed  Google Scholar 

  53. Fatak A. Rules of procedure applicable to medicines used in human medicine to ensure their safety under Algerian law. Egypt Contemp Mag. 2008;100(489):477–507.

    Google Scholar 

  54. Mur S. Medicine and the obligations imposed in its scope. Leg Stud Period Rev. 2013;18:9–28.

    Google Scholar 

  55. Khan LM, Al-Harthi SE, Saadah OI. Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharm J. 2013;21(3):261–6.

    Article  PubMed  Google Scholar 

  56. Wilbur K. Pharmacovigilance in Qatar hospitals. Pharm Med. 2012;26(1):23–5.

    Article  Google Scholar 

  57. Al-Essa R, Al-Rubaie M, Walker S, Salek S. Pharmaceutical regulatory environment: challenges and opportunities in the Gulf region. 1st ed. Cham: Springer International Publishing; 2015.

    Google Scholar 

  58. Fathelrahman A, Ibrahim M, Wertheimer A. Pharmacy practice in developing countries. 1st ed. London: Academic Press; 2016.

    Google Scholar 

  59. Qato DM. Current state of pharmacovigilance in the Arab and Eastern Mediterranean region: results of a 2015 survey. Int J Pharm Pract. 2017. doi:10.1111/ijpp.12372.

  60. Kohler JC, Ovtcharenko N. Good governance for medicines initiatives: exploring lessons learned. U4 Anti-Corrupt Resour Centre. 2013;3:1-26.

  61. Naffa S, Nuseirat A. Medicine transparency alliance Jordan Workplan. [cited 30 Sept 2017]. http://www.medicinestransparency.org/fileadmin/uploads/Renee/MeTA__Jordan_Workplan.pdf.

  62. World Health Organization. Minimum requirements for a functional pharmacovigilance system. Geneva: WHO; 2010.

    Google Scholar 

  63. Lexchin J. Harmony in drug regulation, but who’s calling the tune? An examination of regulatory harmonization in health Canada. Int J Health Serv. 2012;42(1):119–36.

    Article  PubMed  Google Scholar 

  64. Arthur N, Bentsi-Enchill A, Couper R, Duclos P, Edwards I, Fushimi T, Hartigan-Go K, Folb P, Kshirsagar N, Lazdins-Helds J, Lepahkin V. The importance of pharmacovigilance-safety monitoring of medicinal products. Geneva: World Health Organization; 2002.

    Google Scholar 

  65. Forman L, Kohler JC. Access to medicines as a human right: implications for pharmaceutical industry responsibility. Toronto: University of Toronto Press; 2012.

    Google Scholar 

  66. World Health Organization. WHO pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems. Geneva, Switzerland: WHO; 2015.

Download references

Acknowledgements

English language editing of the manuscript was undertaken by American Journal Experts.

Author information

Authors and Affiliations

  1. Clinical Pharmacy and Practice Section, College of Pharmacy, Qatar University, Al Hala Street, Doha, Qatar

    Abeer Abdullah Hamid & Mohamed Izham Mohamed Ibrahim

Authors
  1. Abeer Abdullah Hamid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed Izham Mohamed Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Izham Mohamed Ibrahim.

Ethics declarations

Funding

This systematic scoping review was funded by Qatar University (Grant number: QUST-2-CPH-2017-7).

Conflict of interest

MI and AH have no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 59 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamid, A.A., Mohamed Ibrahim, M.I. A Systematic Scoping Review of the State of Pharmacovigilance and Governance in the MENA Region: Challenges and Opportunities. Pharm Med 31, 437–454 (2017). https://doi.org/10.1007/s40290-017-0212-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40290-017-0212-8

Search

Navigation